Deal Watch: LEO Pharma Expands Market Reach Through Bayer Dermatology Deal
Executive Summary
LEO Pharma is buying branded topical treatments worth more than €280m in annual sales from Bayer. Also, Apricus and Sellos agree to merge, Lilly partners on translation inhibitors with Anima, and Merck leverages Sutro's technology in cancer and autoimmune partnership.
You may also be interested in...
Bayer Consumer Chief Identifies 'Root Causes' Of Slump, Initiates Growth 'Fix'
Bayer's Consumer Health chief Heiko Schipper hopes a focus on innovation and a leaner portfolio will help return business to mid-single-digit growth by 2022. German firm has identified North American business as the "key area to fix."
Glenmark Snaps Up Exeltis Derma Range, Sets Base For US Brands Play
Glenmark Pharmaceuticals has tiptoed into the US branded dermatology segment by buying out a range of products from Exeltis. It hopes to build on this base with additional assets, alongside its generics business.
Bayer's Consumer Chief Initiates Turnaround Plan In Bid To Return Troubled Business To Growth
Bayer's Consumer Health chief Heiko Schipper is hoping a focus on innovation and a leaner portfolio will help return the business to mid-single-digit growth by 2022. The German firm has identified its North American business as the 'key area to fix'.